Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsPediatric Statin Administration: Navigating a Frontier with Limited DataModeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro dataAdherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register studyPharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Impact of OATP transporters on pharmacokinetics.HIV and HAART-Associated DyslipidemiaDrug-drug interaction studies: regulatory guidance and an industry perspectiveTransporter-mediated uptake into cellular compartments.Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.Role of OATP transporters in the disposition of drugs.Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.Fenofibrate: treatment of hyperlipidemia and beyond.Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.Does simvastatin cause more myotoxicity compared with other statins?Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Drug-drug interactions that interfere with statin metabolism.Gemfibrozil in Combination with Statins-Is It Really Contraindicated?Rifapentine for the treatment of latent tuberculosis.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism.Clinical efficacy and cost-effectiveness of rosuvastatin.Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2.Concomitant Use of Carbamazepine and Rifampin in a Patient With Mycobacterium avium Complex and Seizure Disorder.
P2860
Q24631021-447CBEB0-0B66-4D8D-94A6-45F074D28232Q28068014-308E277A-B8BD-4FB9-8253-39B7C47C9752Q28533793-FBF5AD39-AE9B-4D15-9B68-2EF6430BDADAQ28535157-14E872BE-A9F7-440C-8342-67EA517CBAF7Q33585344-3DB791F9-B78C-4DF6-83E3-A7CDC29B29CAQ34612244-30361BA8-8A5F-48FE-9D00-C051512DF6BEQ35020217-B1919A2F-D219-4ECF-BE70-65B568895083Q36951933-D9FF4F25-9B00-4EAB-9A9A-AACEA98D66A7Q36985076-92AFC0E3-483E-494E-BE68-592E695A05F6Q37017426-F27DC4BE-77F3-40F5-A4E8-93C41B1A373DQ37074085-05089A59-F352-4B40-A9B8-227234EE903FQ37130938-9C186B5C-BD4C-4020-83C2-591A767A220DQ37329141-15308B87-5AC0-4B5A-A930-596A864314BAQ37367666-5E0FDB3C-651D-4E65-A409-7C55D576EC40Q37634190-6DA3CD52-0ACE-4835-ACBF-64EF9C2A65AEQ37696476-BD247844-02F8-452D-ABB3-0469634392F8Q37960129-990B6BE1-F61D-43F3-B764-B27F04EEB31DQ38155218-3BFB94AB-1902-4E81-8318-1B01BC714A90Q38233298-26C55500-34B6-4420-BA85-133F4BF748EAQ38522299-DCB26E31-FC65-42A4-919B-3664F1AEC10BQ38756974-E24BB708-A30E-40E2-AD85-185DB1A32350Q38933165-2B692273-769F-4BBE-AEA2-9597A8EE64FAQ38933872-95C2B0A7-0250-4797-ABB5-638B495C5D0DQ39178447-1180F9EF-CDE3-470F-9B0D-5C1332C8677FQ39474573-24063C61-F126-4778-A65A-E28A120CB264Q40620508-CBF7B7AD-C49E-41E4-BF36-B137A7878D35Q42705555-20DA8EF9-AB4F-4729-A791-4E46D11C5EBCQ43042803-456D37D9-D842-4B39-9C5C-BF1B61441538Q43231742-7469CB31-7C03-4ACA-AFB8-C7D5B103B3D9Q44991444-157E4FEC-F078-4380-8F6C-07B96FDC1801Q46294694-5150BBBD-2636-4AF2-93F1-FA6892BA8621Q48301397-326E9B86-A92F-4EAC-A32B-7F11F380B82BQ48677705-4D2DCDEF-D711-455D-B597-6EDB44DB8427Q53180947-6D2D6E7A-2ED1-4111-9E9E-822A9F32D15BQ55485640-BAC39BDF-EA7B-469E-998D-480664F2D221
P2860
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@ast
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@en
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@nl
type
label
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@ast
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@en
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@nl
prefLabel
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@ast
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@en
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@nl
P50
P1476
Rifampin markedly decreases an ...... rvastatin and its metabolites.
@en
P2093
Harri Luurila
P304
P356
10.1016/J.CLPT.2005.04.007
P407
P577
2005-08-01T00:00:00Z